Acuitas Therapeutics is a pioneer in developing lipid nanoparticals, and already has seen two approved products: ONPATTRO and the Pfizer/BioNTech mRNA vaccine
Co-Founder & CEO Thomas Madden describes the science and history behind LNPs, and discusses what is currently in development, including trying to use them to deliver therapies outside of the liver.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.